Trial Profile
A double-blind, randomised, placebo-controlled, 4‑way cross-over Phase I study to investigate the pharmacokinetics, pharmacodynamics and safety of escalating single doses of E‑52862 in young healthy male and female subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 May 2016
Price :
$35
*
At a glance
- Drugs E 52862 (Primary)
- Indications Acute pain; Neuropathic pain; Pain
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 16 May 2016 Pooled results of the phase I programme (see profiles 57703, 222641,57701) published in the Mundipharma media release.
- 06 Sep 2012 New trial record